Providers/Grant Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals, Inc.
Credits Available
- Physicians — maximum of 0.5 AMA PRA Category 1 CreditsTM
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Program Overview
This 30-minute symposium from the 2025 Pediatrics360 Virtual Conference takes a closer look at biologic therapies that can address the immune pathophysiology, associated comorbidities, and progression of moderate-to-severe atopic dermatitis in pediatric patients.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Discuss the burden of moderate-to-severe atopic dermatitis (AD) and its associated comorbidities on pediatric patients’ quality of life
- Identify the immune pathways implicated in the pathophysiology of moderate-to-severe AD
- Apply recent clinical data for biologic therapies into the management of pediatric moderate-to-severe AD in order to prevent progression
Faculty
Peter Lio, MD
Clinical Assistant Professor of Dermatology
Northwestern University Feinberg School of Medicine
Chicago, IL
Elizabeth (Lisa) Swanson, MD
Ada West Dermatology,
St Luke's Children's Hospital;
Ada West, Research Group
Boise, ID
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Faculty Name
Peter A. Lio, MD
No relevant financial relationships with any Ineligible Company in the past 24 months.
Elizabeth (Lisa) A. Swanson, MD
Consultant: Janssen, Lilly, Ortho Dermatologics, Sanofi-Regeneron, Pfizer, LEO, Novan, Arcutis
Speakers’ Bureau or Honoraria: Ortho Dermatologics, Pfizer, Amgen, Sanofi-Regeneron, Almirall, Janssen, Lilly, Novartis, Abbvie, Incyte
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.
Instructions For Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be immediately available to the participant.
Disclosure of Unlabeled Use
The Institute requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected]